Frederico Teixeira

Frederico Teixeira

Auto-generated profile, based on publicly available information

Frederico Teixeira

Laboratory of Pharmacology & Experimental Therapeutics, IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal

Research Focus & Metrics

Academic Career Length

46Years (1981-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2011 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
Edite Teixeira-LemosEdite Teixeira-Lemos
Edite Teixeira-Lemos
SNSara Nunes
Sara Nunes
FTFrederico Teixeira
Frederico Teixeira
Flávio ReisFlávio Reis
Flávio Reis
Diabetes mellitus has emerged as one of the main alarms to human health in the 21st century. Pronounced changes in the human environment, behavior and lifestyle have accompanied globalization, which resulted in escalating rates of both obesity and diabetes, already described as diabesity. This pandemic causes deterioration of life quality with high socio-economic costs, particularly due to premature morbidity and mortality. To avoid late complications of type 2 diabetes and related costs, primary prevention and early treatment are therefore necessary. In this context, effective non-pharmacological measures, such as regular physical activity, are imperative to avoid complications, as well as polymedication, which is associated with serious side-effects and drug-to-drug interactions.Our previous work showed, in an animal model of obese type 2 diabetes, the Zucker Diabetic Fatty (ZDF) rat, that regular and moderate intensity physical exercise (training) is able, per se, to attenuate insulin resistance and control glycaemia, dyslipidaemia and blood pressure, thus reducing cardiovascular risk, by interfering with the pathophysiological mechanisms at different levels, including oxidative stress and low-grade inflammation, which are key features of diabesity.This paper briefly reviews the wide pathophysiological pathways associated with Type 2 diabetes and then discusses in detail the benefits of training therapy on glycaemic control and on cardiovascular risk profile in Type 2 diabetes, focusing particularly on antioxidant and anti-inflammatory properties. Based on the current knowledge, including our own findings using an animal model, it is concluded that regular and moderate intensity physical exercise (training), due to its pleiotropic effects, could replace, or at least reduce, the use of anti-diabetic drugs, as well as of other drugs given for the control of cardiovascular risk factors in obese type 2 diabetic patients, working as a physiological "polypill".

17 May 2004 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
PRP. Rocha-Pereira
P. Rocha-Pereira
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva
IRIrene Rebelo
Irene Rebelo
AFA. Figueiredo
A. Figueiredo
AQA. Quintanilha
A. Quintanilha
FTF. Teixeira
F. Teixeira

1 January 2010 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
LFLiliana Ferreira
Liliana Ferreira
Edite Teixeira-LemosEdite Teixeira-Lemos
Edite Teixeira-Lemos
FPFilipa Pinto
Filipa Pinto
BPBelmiro Parada
Belmiro Parada
CMCristina Mega
Cristina Mega
Flávio ReisFlávio Reis
Flávio Reis
The purpose of this paper is to evaluate the chronic effect of sitagliptin on metabolic profile, inflammation, and redox status in the Zucker Diabetic Fatty (ZDF) rat, an animal model of obese type 2 diabetes. Diabetic and obese ZDF (fa/fa) rats and their controls (ZDF +/+) were treated during 6 weeks with vehicle (control) and sitagliptin (10 mg/kg/bw). Glucose, HbA1c, insulin, Total-c, TGs, IL-1β, TNF-α, CRPhs, and adiponectin were assessed in serum and MDA and TAS in serum, pancreas, and heart. Pancreatic histology was also evaluated. Sitagliptin in diabetic rats promoted a decrease in glucose, HbA1c, Total-c, and TGs accompanied by a partial prevention of insulinopenia, together, with a decrease in CRPhsand IL-1β. Sitagliptin also showed a positive impact on lipid peroxidation and hypertension prevention. In conclusion, chronic sitagliptin treatment corrected the glycaemic dysmetabolism, hypertriglyceridaemia, inflammation, and hypertension, reduced the severity of the histopathological lesions of pancreatic endocrine and exocrine tissues, together with a favourable redox status, which might be a further advantage in the management of diabetes and its proatherogenic comorbidities.

1 May 2013 in Applied Clay Science
Verified
Journal Article
Closed access
CGCelso Gomes
Celso Gomes
MLMaría Isabel Carretero León
María Isabel Carretero León
Manuel PozoManuel Pozo
Manuel Pozo
Francisco MaraverFrancisco Maraver
Francisco Maraver
PCPedro Cantista
Pedro Cantista
RDRafael Delgado
Rafael Delgado

1 January 2001 in Clinica Chimica Acta
Verified
Journal Article
Closed access
PRPetronila Rocha-Pereira
Petronila Rocha-Pereira
Alice Santos-SilvaAlice Santos-Silva
Alice Santos-Silva
IRIrene Rebelo
Irene Rebelo
AFAmérico Figueiredo
Américo Figueiredo
AQAlexandre Quintanilha
Alexandre Quintanilha
FTFrederico Teixeira
Frederico Teixeira

30 November 2011 in Experimental Diabetes Research
Verified
Journal Article
Open access
PDF file
CMCristina Mega
Cristina Mega
Edite Teixeira-LemosEdite Teixeira-Lemos
Edite Teixeira-Lemos
HVHelena Vala
Helena Vala
Rosa FernandesRosa Fernandes
Rosa Fernandes
Jorge OliveiraJorge Oliveira
Jorge Oliveira
Flávio ReisFlávio Reis
Flávio Reis
This study was performed to assess the effect of chronic low-dose sitagliptin, a dipeptidyl peptidase 4 inhibitor, on metabolic profile and on renal lesions aggravation in a rat model of type-2 diabetic nephropathy, the Zucker diabetic fatty (ZDF) rat. Diabetic and obese ZDF (fa/fa) rats and their controls ZDF (+/+) were treated for 6 weeks with vehicle (control) or sitagliptin (10 mg/kg/bw). Blood/serum glucose, HbA1c, insulin, Total-c, TGs, urea, and creatinine were assessed, as well as kidney glomerular and tubulointerstitial lesions (interstitial fibrosis/tubular atrophy), using a semiquantitative rating from 0 (absent/normal) to 3 (severe and extensive damage). Vascular lesions were scored from 0–2. Sitagliptin in the diabetic rats promoted an amelioration of glycemia, HbA1c, Total-c, and TGs, accompanied by a partial prevention of insulinopenia. Furthermore, together with urea increment prevention, renal lesions were ameliorated in the diabetic rats, including glomerular, tubulointerstitial, and vascular lesions, accompanied by reduced lipid peroxidation. In conclusion, chronic low-dose sitagliptin treatment was able to ameliorate diabetic nephropathy, which might represent a key step forward in the management of T2DM and this serious complication.